(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202112 | 202012 | % Var | 202112 | 202012 | % Var | 202103 | 202003 | % Var | |
| Sales | 44.75 | 32.54 | 37.52 | 147.20 | 123.94 | 18.77 | 137.40 | 119.79 | 14.70 |
| Other Income | 0.99 | 1.17 | -15.38 | 1.74 | 1.52 | 14.47 | 4.60 | 3.00 | 53.33 |
| PBIDT | 2.00 | 1.70 | 17.65 | 7.91 | 8.73 | -9.39 | 8.17 | 8.46 | -3.43 |
| Interest | 0.03 | 0.02 | 50.00 | 0.10 | 0.06 | 66.67 | 0.09 | 0.07 | 28.57 |
| PBDT | 1.93 | 1.68 | 14.88 | 7.77 | 8.67 | -10.38 | 8.08 | 8.39 | -3.69 |
| Depreciation | 0.96 | 0.63 | 52.38 | 2.61 | 1.73 | 50.87 | 2.50 | 2.54 | -1.57 |
| PBT | 0.97 | 1.05 | -7.62 | 5.16 | 6.94 | -25.65 | 5.58 | 5.85 | -4.62 |
| TAX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.18 | 0.19 | 521.05 |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.16 | -0.04 | 300.00 |
| PAT | 0.97 | 1.05 | -7.62 | 5.16 | 6.94 | -25.65 | 4.40 | 5.66 | -22.26 |
| Equity | 53.74 | 53.74 | 0.00 | 53.74 | 53.74 | 0.00 | 53.74 | 53.74 | 0.00 |
| PBIDTM(%) | 4.47 | 5.22 | -14.45 | 5.37 | 7.04 | -23.71 | 5.95 | 7.06 | -15.81 |
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1850.40 |
| Dr. Reddys Lab | 1310.50 |
| Cipla | 1365.25 |
| Zydus Lifesciences | 939.10 |
| Lupin | 2442.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: